Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana D Fernandes

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Genome Medicine|March 2, 2021
Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosisDamian R Plichta, Juhi Somani, Matthieu Pichaud, et al.
Annals of the Rheumatic Diseases|July 30, 2024
Multiorgan involvement and circulating IgG1 predict hypocomplementaemia in IgG4-related diseaseGuy Katz, Cory Perugino, Zachary S Wallace, et al.
The Lancet. Rheumatology|January 22, 2024
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trialCory A Perugino, Zachary S Wallace, Debra J Zack, et al.
The New England Journal of Medicine|October 21, 2020
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19John H Stone, Matthew J Frigault, Naomi J Serling-Boyd, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Genome Medicine|March 2, 2021
Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosisDamian R Plichta, Juhi Somani, Matthieu Pichaud, et al.
Annals of the Rheumatic Diseases|July 30, 2024
Multiorgan involvement and circulating IgG1 predict hypocomplementaemia in IgG4-related diseaseGuy Katz, Cory Perugino, Zachary S Wallace, et al.
The Lancet. Rheumatology|January 22, 2024
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trialCory A Perugino, Zachary S Wallace, Debra J Zack, et al.
The New England Journal of Medicine|October 21, 2020
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19John H Stone, Matthew J Frigault, Naomi J Serling-Boyd, et al.
Pageof 2